Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 43

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---

			109,647

			Accounts payable and accrued liabilities

			(1,117,921
			)

			533,044

			Net cash used in operating activities

			(5,601,268
			)

			(3,923,166
			)

			Cash flows from financing activities:

			Proceeds from issuance of common shares and warrants

			7,497,133

			729,387

			Proceeds from issuance of Series A-1 preferred shares and warrants

			1,540,820

			-

			Proceeds from issuance of Series B-1 preferred shares

			8,340,000

			-

			Payments for issuance costs of common shares and warrants

			(294,935
			)

			(76,389
			)

			Payment for issuance costs of preferred shares

			(215,157
			)

			-

			Payment for issuance costs of warrants

			(23,446
			)

			-

			Repayment of debt

			-

			(29,532
			)

			Net cash provided by financing activities

			16,844,415

			623,466

			Effect of exchange rate changes on cash and cash equivalents

			81,223

			(20,813
			)

			Net change in cash and cash equivalents

			11,324,370

			(3,320,513
			)

			Cash and cash equivalents, beginning of period

			1,037,320

			5,361,397

			Cash and cash equivalents, end of period

			$
			12,361,690

			$
			2,040,884

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

5

Edesa Biotech, Inc.

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

			Shares #

			Common Shares

			Series A-1 Preferred Shares 

			Series B-1 Preferred Shares 

			Additional Paid-in Capital

			Accumulated Other Comprehensive Loss

			Accumulated Deficit

			Total Shareholders' Equity

			Three Months Ended June 30, 2025

			Balance - March 31, 202